💊 Препараты А-Я 🧬 Мишени 🛠 Инструменты 📚 Руководства
Все препараты Классы препаратов Терапевтические области Побочные Эффекты
Руководства Глоссарий Хронология
Сравнения Путешествия препаратов Группы лекарственных средств
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Sacituzumab Govitecan

CHEMBL3545262 Phase 4 Одобрено Antibody drug conjugate
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

Sacituzumab govitecan is an antibody-drug conjugate (ADC) consisting of a humanized anti-Trop-2 antibody linked to SN-38, the active metabolite of irinotecan, a topoisomerase I inhibitor. It is approved for the treatment of metastatic triple-negative breast cancer and advanced urothelial (bladder) cancer that has progressed on prior therapy. The ADC delivers cytotoxic SN-38 directly to Trop-2-expressing tumor cells, achieving tumor-selective cytotoxicity.

Терапевтические области

Oncology Breast Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Часто задаваемые вопросы

Sacituzumab govitecan is an antibody-drug conjugate (ADC) consisting of a humanized anti-Trop-2 antibody linked to SN-38, the active metabolite of irinotecan, a topoisomerase I inhibitor. It is approved for the treatment of metastatic triple-negative breast cancer and advanced urothelial (bladder) cancer that has progressed on prior therapy. The ADC delivers cytotoxic SN-38 directly to Trop-2-expressing tumor cells, achieving tumor-selective cytotoxicity.

Yes, Sacituzumab Govitecan is an approved drug. It has reached clinical phase 4. It is classified as a Antibody drug conjugate.

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3545262. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.

Медицинский отказ от ответственности

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.